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In the past few years, we have witnessed and been excited
by biotechnological advances that allow for the precise edit-
ing of genomic information in living eukaryotic cells. Fa-
cilitated by TALEN (transcription activator-like effector
nucleases) or CRISPR (clustered regularly interspaced short
palindromic repeats) systems, scientists can now routinely
perform gene-editing in a variety of organisms including
plants, insects, rodents and primates, as well as in human
somatic cells in basic research. These innovative techniques
have opened up new opportunities for scientiﬁc discovery
and human disease therapeutic development that were not
possible just a few years ago. Recently, scientists try to apply
the gene-editing techniques to human germ cells and em-
bryos, hoping to prevent the transmission of inherited dis-
eases to the next generation in the future. However, these
rapid advances in the capability of genomic manipulation
have begun to outpace the scope of existing regulatory
agencies and laws. As recently attested by prominent sci-
entists in the ﬁeld, in light of safety and ethical concerns as-
sociated with potential applications of these gene-editing
techniques, it is time for the scientiﬁc community, public,
funding bodies and governments to come together to re-de-
ﬁne and reinforce the boundaries of gene-editing research.
With extraordinary care, consideration and deliberation,
Protein & Cell has decided to publish in this issue a scientiﬁc
study that reports CRISPR-based gene-editing of human
tripronuclear zygotes (fertilized zygotes with one oocyte
nucleus and two sperm nuclei). Utilizing tripronuclear
zygotes, which occur in common in vitro fertilization (IVF)
procedures and are clinically discarded because they are
unable to develop at later stages, the authors demonstrate
that CRISPR-based gene-editing can be achieved in this
setting. However, the authors also report notable off-target
effects of CRISPR-based gene-editing, low efﬁciency of
homologous recombination directed repair (HDR), mosacism
and unwanted mutations, substantiating the concerns that
the therapeutic application of these new techniques could
have unpredictable safety risks. Because germline modiﬁ-
cation is permanent and heritable, it should be given the
particular concerns. Protein & Cell has fully realized that this
study can provide direct evidences to address some of the
safety concerns of the CRISPR/Cas9 technique. It may also
raise a series of questions and bring further controversies to
the ﬁeld of gene-editing research. In this unusual situation,
the editorial decision to publish this study should not be
viewed as an endorsement of this practice nor an encour-
agement of similar attempts, but rather the sounding of an
alarm to draw immediate attention to the urgent need to rein
in applications of gene-editing technologies, especially in the
human germ cells or embryos.
Biomedical research is not unfamiliar with such contro-
versies; in fact, many landmark breakthroughs have been
met with safety, legal and ethical questions. This was the
case for the IVF procedure and recombinant DNA techniques
in the 1970s, the mammalian cloning technique (i.e., the birth
of the Dolly sheep) in the 1990s, the generation of inducible
pluripotent stem cells (iPSC) in the 2000s and mitochondrial
DNA (mtDNA) transfer in embryos in 2013, to name just a few
in recent memory. Those past scientiﬁc and public debates
should not only serve as successful precedents that the
dialogue on gene-editing technologies will follow, but also
offer us the courage, conﬁdence and wisdom to solve the
challenges we are currently facing. By working together with
both the public and governments, the research community
should immediately and comprehensively assess the bene-
ﬁts and risks associated with any potential application of
gene-editing techniques. Until a consensus on new regula-
tory rules can be reached, it is in the best interest of all parties
that the research ﬁeld should voluntarily avoid any study that
may pose potential safety and/or ethical risks. Only by hold-
ing themselves to the highest standards will scientists retain
the public’s trust in biomedical research, and at the same
time, provide the best service for the well-being of our society.
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